Literature DB >> 15232137

The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.

M Kiupel1, J D Webster1, J B Kaneene, R Miller, V Yuzbasiyan-Gurkan.   

Abstract

Cutaneous mast cell tumors (MCTs) are one of the most common tumors in dogs. Currently, prognostic and therapeutic determinations for MCTs are primarily based on the histologic grade of the tumor, but a vast majority of MCTs are of an intermediate grade, and the prognostic relevance is highly questioned. A more detailed prognostic evaluation, especially of grade 2 canine MCTs, is greatly needed. To evaluate the prognostic significance of KIT and tryptase expression patterns in canine cutaneous MCTs, we studied 100 cutaneous MCTs from 100 dogs that had been treated with surgery only. The total survival and disease-free survival time and the time to local or distant recurrence of MCTs were recorded for all dogs. Using immunohistochemistry, 98 of these MCTs were stained with anti-KIT and antitryptase antibodies. Three KIT- and three tryptase-staining patterns were identified. The KIT-staining patterns were identified as 1) membrane-associated staining, 2) focal to stippled cytoplasmic staining with decreased membrane-associated staining, and 3) diffuse cytoplasmic staining. The tryptase-staining patterns were identified as 1) diffuse cytoplasmic staining, 2) stippled cytoplasmic staining, and 3) little to no cytoplasmic staining. Based on univariate and multivariate survival analysis, increased cytoplasmic KIT staining was significantly associated with an increased rate of local recurrence and a decreased survival rate. The tryptase-staining patterns were not significantly associated with any survival parameter. On the basis of these results, we propose a new prognostic classification of canine cutaneous MCTs, according to their KIT-staining pattern, that can be used for the routine prognostic evaluation of canine cutaneous MCTs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232137     DOI: 10.1354/vp.41-4-371

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  37 in total

Review 1.  Systemic mastocytosis with subcutaneous hemorrhage and edema in a Greyhound dog: case report and review of diagnostic criteria.

Authors:  Alexander Aceino; Unity Jeffery; Julie Piccione; Carolyn L Hodo
Journal:  J Vet Diagn Invest       Date:  2020-11-09       Impact factor: 1.279

2.  Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology.

Authors:  Ehsan Hosseini; Behnam Pedram; Ali Mohammad Bahrami; Seyed Rashid Touni; Hamed Zamankhan Malayeri; Aram Mokarizadeh; Mehdi Pourzaer; Maryam Pourzaer; Shahram Zehtabian; Sheida Mohajer; Sharareh Ahmadi
Journal:  Tumour Biol       Date:  2014-10-15

3.  In vitro inhibitory effect of trichostatin A on canine grade 3 mast cell tumor.

Authors:  Marcia Kazumi Nagamine; Daniel S Sanches; Katia C Pinello; Luciana Neves Torres; Gregory Mennecier; Andréia O Latorre; Heidge Fukumasu; Maria Lucia Zaidan Dagli
Journal:  Vet Res Commun       Date:  2011-04-07       Impact factor: 2.459

4.  The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors.

Authors:  Joshua D Webster; Vilma Yuzbasiyan-Gurkan; John B Kaneene; RoseAnn Miller; James H Resau; Matti Kiupel
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

5.  In vitro chemosensitivity of canine mast cell tumors grades II and III to all-trans-retinoic acid (ATRA).

Authors:  K C Pinello; M Nagamine; T C Silva; P Matsuzaki; H V Caetano; L N Torres; H Fukumasu; J L Avanzo; J M Matera; M L Z Dagli
Journal:  Vet Res Commun       Date:  2009-01-14       Impact factor: 2.459

Review 6.  Comparative oncology today.

Authors:  Melissa C Paoloni; Chand Khanna
Journal:  Vet Clin North Am Small Anim Pract       Date:  2007-11       Impact factor: 2.093

7.  Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.

Authors:  Giacomo Rossi; Chiara Bertani; Subeide Mari; Carlotta Marini; Giacomo Renzoni; Gregory Ogilvie; Gian Enrico Magi
Journal:  Vet Res Commun       Date:  2013-01-13       Impact factor: 2.459

8.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

9.  Molecular diagnosis using RNAscope in-situ hybridization in canine malignancies.

Authors:  Keijiro Shiomitsu; Sandra M Bechtel; Patrick M Thompson; Salvatore Frasca
Journal:  Can J Vet Res       Date:  2020-10       Impact factor: 1.310

10.  IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

Authors:  K Bauer; E Hadzijusufovic; S Cerny-Reiterer; G Hoermann; M Reifinger; A Pirker; P Valent; M Willmann
Journal:  Vet Comp Oncol       Date:  2016-08-09       Impact factor: 2.613

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.